article thumbnail

Medtech: BrainTale Gathers €4.5 Million to Accelerate the Development of Its Solution for Diagnosis, Monitoring and Prediction of Neurological Disorders

Digital Health Global

Founded in 2018 and supported from the outset by LallianSe, the life sciences integrator, BrainTale has developed and commercializes an accessible, reliable and clinically validated brain measurement digital platform solution for drug developers and physicians – neurologists, neuroradiologists and intensivists.

article thumbnail

6 challenges healthtech can help us tackle – Pt.2

Digital Health Global

Drug development The traditional drug discovery process is characterized by its protracted timeline, high costs, and significant attrition rates among drug candidates. There are three main advantages to the use of AI in drug development: width of research, speed of execution, low costs. DiMasi, H.G.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Leveraging T2D Drugs to improve T1D Therapy

Insulin Nation

In his studies, Type 1 diabetic patients have significantly benefited when their daily insulin regimen is supplemented with drugs developed to treat Type 2 diabetes. This was the first research ( release ) on using this Type 2 approved drug for T1D treatment and there were larger confirmatory studies ( release ) in 2016 and 2018.

article thumbnail

Auxulin: Hyperglycemic Innovation Driven by Need

Insulin Nation

The idea behind Auxulin came to Ritz in the winter of 2016 on the day following a hyperglycemic episode that saw his blood sugar soar to 500. Economics of Development and Marketing. Ritz and McDevitt estimate that it will take $35 million to fund drug development through Phase III trials and FDA submission.

article thumbnail

Genomics Startup Human Longevity’s Valuation Falls 80% from $1.6 Billion down to $310M

Lloyd Price

But key facets of its business didn’t develop as planned, say people familiar with the company. It had hoped to sell analytics to pharmaceutical companies as they increasingly incorporated genetic sequencing into drug development, these people say.

article thumbnail

Teladoc Livongo merger: what went wrong with the 'one-stop shop for virtual care' strategy?

Lloyd Price

2016: Livongo launches its diabetes management platform. As the ability to collect and analyze large amounts of patient data grows, there is a growing opportunity for companies to develop personalized treatments and care plans. This could create a company that is able to develop and deliver personalized treatments to patients.

article thumbnail

The outlook for healthcare in 2022

Waracle

billion in funding, and the fastest-growing subsector in London is remote monitoring and wearables, raising $345 million in 2021, which is 20 times more than what it was in 2016. . In fact, Exscientia stands by the claim that all drugs in the future will be made using AI. . London health tech startups secured a staggering $2.9